Navigation Links
SXC Health solutions announces Strong fourth quarter and year end financial results
Date:3/4/2010

    -   Revenue increased 51% in Q4-2009 compared to Q4-2008
    -   Cash from operations increased 75% in Q4-2009 compared to Q4-2008
    -   EPS grew 165% in 2009 compared to 2008

LISLE, IL, March 4 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ("SXC" or the "Company") ( SXCI, TSX: SXC), announces its financial results for the three- and twelve-month periods ended December 31, 2009. Financial references are in U.S. dollars unless otherwise indicated.

    2009 Financial Highlights
    -------------------------
    -   Revenue was $1.4 billion in 2009 compared to $862.9 million in 2008
    -   Gross profit was $186.6 million in 2009 compared to $115.5 million in
        2008
    -   Adjusted EBITDA(1) was $94.7 million in 2009 compared to $42.5
        million in 2008
    -   GAAP net income increased to $46.1 million, or $1.72 per share
        (fully-diluted), in 2009 compared to $15.1 million, or $0.65 per
        share (fully-diluted), in 2008
    -   Non-GAAP adjusted earnings per share(1) (diluted), which excludes the
        NMHC transaction-related amortization net of tax, was $1.91 in 2009
        compared to $0.89 in 2008
    -   Cash from operations was $86.4 million in 2009 compared to $41.6
        million in 2008
    -   Adjusted prescription claim volume(1) for the PBM segment was 11.1
        million in Q4-2009 compared to 9.9 million in Q3-2009
    -   Gross margin per adjusted prescription for the PBM segment was $3.47
        in Q4-2009 compared to $3.35 in Q4-2008
    -   Mail order penetration increased to 11% in Q4-2009 compared to 9.5%
        in Q3-2009
    -   Transaction processing volume for the HCIT segment was 94.6 million
        in Q4-2009 compared to 92.0 million in Q3-2009

    2009 Corporate Highlights
    -------------------------

    -   Awarded new business with the Ohio Bureau of Workers' Compensation,
        the UFCW & Employers Benefit Trust, the Commonwealth of Virginia,
        Presbyterian Health Plan, Spectral Solutions, Prime Therapeutics LLC
        and PharMerica Corporation
    -   Renewed a multi-year PBM contract with the Employer-Union Health
        Benefits Trust Fund of Hawaii
    -   Entered into a strategic relationship with Allscripts Misys to
        enhance the E-Prescribing options available to SXC's clients
    -   Completed a public offering of 5,175,000 common shares at a price of
        $41.50 per share resulting in net proceeds of approximately $203.1
        million

"2009 was an outstanding year with record financial and operational achievements for SXC," said Mark Thierer, President and CEO. "We won new contracts with industry leaders, locked-in new commitments with existing customers and completed a $203 million equity financing that will help us capitalize on future growth opportunities, both organically and through acquisitions. As we enter 2010, the healthcare system is under intense scrutiny to provide enhanced services while improving efficiencies. The rate of change is extreme which opens new opportunities to agile and expert players in our industry. We are well positioned at the leading edge of this curve with a unique business model for providing technology solutions and PBM services that enable us to meet the individual needs of a diverse and growing set of payor customers."

    Financial Review
    ----------------

SXC evaluates segment performance based on revenue and gross profit. A reconciliation of the Company's business segments to the consolidated financial statements for the three- and twelve-month periods ended December 31, 2009 and 2008 is as follows(2):

Three months ended December 31, (in thousands)

PBM HCIT Consolidated

--------------------- --------------------- ---------------------

2009 2008 2009 2008 2009 2008

---------- ---------- ---------- ---------- ---------- ----------

Revenue $ 416,803 $ 269,802 $ 26,513 $ 22,964 $ 443,316 $ 292,766

revenue 378,149 241,633 12,643 13,853 390,792 255,486

---------- ---------- ---------- ---------- ---------- ----------

profit $ 38,654 $ 28,169 $ 13,870 $ 9,111 $ 52,524 $ 37,280

profit % 9.3% 10.4% 52.3% 39.7% 11.8% 12.7%

Twelve months ended December 31, (in thousands)

PBM HCIT Consolidated

--------------------- --------------------- ---------------------

2009 2008 2009 2008 2009 2008

---------- ---------- ---------- ---------- ---------- ----------

Revenue $1,335,961 $ 771,840 $ 102,673 $ 91,099 $1,438,634 $ 862,939

revenue 1,197,757 702,333 54,277 45,120 1,252,034 747,453

profit $ 138,204 $ 69,507 $ 48,396 $ 45,979 $ 186,600 $ 115,486

profit % 10.3% 9.0% 47.1% 50.5% 13.0% 13.4%

PBM Revenue

PBM revenue increased 73% to $1.3 billion in 2009, compared to $771.8 million in 2008. PBM revenue was $416.8 million in Q4-2009 compared to $269.8 million in Q4-2008. PBM revenue increased due to the inclusion of a full year of revenue related to the NMHC business as compared to only eight months for the same period in 2008. In addition, the Company successfully converted several HCIT customers to full-service PBM customers.

HCIT Revenue

HCIT revenue increased 12.7% to $102.7 million in 2009, compared to $91.1 million in 2008. Recurring revenue in 2009 consisted of transaction processing revenue of $61.2 million, compared to $52.8 million in 2008, and maintenance revenue of $18.4 million, compared to $16.4 million in 2008. Recurring revenue accounted for 78% of HCIT revenue in 2009, compared to 76% in 2008. Non-recurring revenue in 2009 consisted of professional service revenue of $15.3 million, compared to $13.5 million in 2008, and system sales revenue of $7.7 million, compared to $8.4 million in 2008.

HCIT revenue increased 15.5% to $26.5 million in Q4-2009, compared to $23.0 million in Q4-2008. Transaction processing revenue was $15.4 million in Q4-2009, compared to $14.6 million in Q4-2008. Maintenance revenue was $4.7 million in Q4-2009, compared to $4.1 million in Q4-2008. Recurring revenue accounted for 76% of HCIT revenue in Q4-2009, compared to 81% in Q4-2008. Professional services revenue was $4.7 million in Q4-2009, compared to $2.8 million in Q4-2008. System sales revenue was $1.7 million in Q4-2009, compared to $1.5 million in Q4-2008.

Product Development Costs

Product development costs were $12.0 million in 2009, compared to $10.1 million in 2008. Product development costs were $2.9 million Q4-2009, compared to $2.7 million in Q4-2008. Product development remains a key priority for SXC as the Company seeks to develop enhancements to existing products and launch new offerings to support its market expansion.

Selling, General and Administration ("SG&A") Costs

SG&A costs were $85.8 million in 2009, compared to $68.8 million in 2008. SG&A costs were $20.9 million Q4-2009, compared to $21.5 million in Q4-2008. On a quarter-over-quarter basis, the Company has added a significant amount of new business while keeping SG&A costs relatively flat. The change in the year-over-year comparison period is largely attributable to the increase in operating expenses related to the acquisition of NMHC.

Adjusted EBITDA(1)

Adjusted EBITDA was $94.7 million in 2009, compared to $42.5 million in 2008. Adjusted EBITDA was $30.4 million in Q4-2009, compared to $14.7 million in Q4-2008. The year-over-year growth in adjusted EBITDA was related primarily to new contract wins, improved purchasing efficiencies on prescription drugs, the acquisition of the NMHC business, and cost and revenue synergies generated from the acquisition.

Adjusted EBITDA benefited by $3.0 million in the quarter due to unusually high professional services in the HCIT segment as well as recoveries for bad debts and other reserves due to improved collections and reduced employee benefits in the fourth quarter.

Income Taxes

The Company's effective tax rate was 32.3% in 2009, compared to an effective tax rate of 25.6% in 2008. The effective income tax rate increased year-over-year primarily due to greater pre-tax income due to the growth in the business.

Net Income

SXC reported net income of $46.1 million in 2009, or $1.72 per share (fully-diluted), which included $5.1 million of intangible amortization related to the purchase of NMHC, compared to $15.1 million in 2008, or $0.65 per share (fully-diluted), which included $5.8 million of intangible amortization related to the purchase of NMHC. Net income was $15.2 million in Q4-2009, or $0.49 per share (fully-diluted), which included $1.1 million of intangible amortization related to the purchase of NMHC, compared to net income of $5.0 million in Q4-2008, or $0.20 per share (fully-diluted), which included $2.0 million of NMHC intangible amortization.

In Q4-2009, the Company repaid all its outstanding debt in the amount of $45.1 million. The repayment of the debt resulted in one-time charges totalling $1.5 million related to the write-off of deferred financing costs and other debt extinguishment costs that were recorded in interest expense and other income/expense.

Cash from Operations

SXC continues to generate strong cash from operations. SXC generated cash from operations of $86.4 million in 2009, compared to $41.6 million in 2008. The Company's quarterly cash flows can be impacted by the timing of pharmacy deposits and rebate payments it receives for certain customers. The Company generated $36.8 million of cash through its operations in Q4-2009, compared to $21.0 million in Q4-2008.

At December 31, 2009 and 2008, SXC had cash and cash equivalents totalling $304.4 million and $67.7 million, respectively. In Q4-2009, SXC repaid all its outstanding long-term debt obligations. On September 23, 2009, SXC completed a public offering of 5,175,000 of its common shares, including 675,000 shares sold pursuant to the exercise of the underwriters' over-allotment option, for net proceeds to the Company of approximately $203.1 million.

2010 Full Year Financial Guidance

    SXC has set the following financial targets for 2010:
        -  Revenue of $1.9 to $2.0 billion
        -  Gross profit of $195 to $205 million
        -  Adjusted EBITDA of $108 to $112 million
        -  Fully-diluted GAAP EPS of $1.79 to $1.87
        -  Adjusted EPS of $1.92 to $2.00

The full year 2010 guidance as compared to the Q4-09 run rate is reflective of the full dilution of the equity raise completed in September 2009, the repayment of the Company's debt, and takes into account the Q4 benefits outlined above, as well as the impacts related to the Company's known successful renewals.

Notice of Conference Call

SXC will host a conference call on Thursday, March 4, 2010 at 8:30 a.m. EST to discuss its financial results. Mark Thierer, President and CEO, and Jeff Park, EVP and CFO will co-chair the call. All interested parties can join the call by dialing 1-888-231-8191 or 647-427-7450. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until Thursday, March 11, 2010 at midnight. To access the archived conference call, please dial 1-800-642-1687 or 416-849-0833 and enter the reservation code 52168294.

A live audio webcast of the conference call will be available www.sxc.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 365 days.

(1)Non-GAAP Financial Measures

SXC reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP"). SXC's management also evaluates and makes operating decisions using various other measures. Two such measures are adjusted EPS and adjusted EBITDA, which are non-GAAP financial measures. SXC's management believes that these two measures provide useful supplemental information regarding the performance of SXC's business operations.

Adjusted EPS is a non-GAAP measure which takes EPS and adds back the impact of amortization expense related to the acquisition of NMHC, net of tax. Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with the acquisition. SXC excludes acquisition-related amortization expense from non-GAAP adjusted EPS because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of SXC's business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contribute to revenue in the period presented as well as future periods and should also note that such expenses will recur in future periods.

Adjusted EBITDA is a non-GAAP measure that management believes is a useful supplemental measure of operating performance prior to net interest income (expense), income taxes, depreciation, amortization and stock-based compensation. Management believes it is useful to exclude depreciation, amortization and net interest income (expense) as these are essentially fixed amounts that cannot be influenced by management in the short term. In addition, management believes it is useful to exclude stock-based compensation as this is not a cash expense.

The 2010 full year guidance of adjusted EBITDA was computed by taking the Company's earnings before interest, taxes, depreciation and amortization as well as estimated stock compensation expense of $5 million. Adjusted EPS was computed by taking the Company's GAAP EPS (fully-diluted) guidance and adding back the expected impact of NMHC acquisition-related amortization expense totaling $4.0 million (net of an estimated 34% tax rate).

Adjusted prescription volume equals SXC's Mail Service prescriptions multiplied by three, plus its retail and specialty prescriptions. The Mail Service prescriptions are multiplied by three to adjust for the fact that they typically include approximately three times the amount of product days supplied compared with retail prescriptions.

Management believes that adjusted EPS, adjusted EBITDA and adjusted prescription volume provide useful supplemental information to management and investors regarding the performance of the Company's business operations and facilitate comparisons to its historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measures are indicative of the Company's core operating results. Note however, that these items are performance measures only, and do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP, and investors and potential investors are encouraged to review the reconciliation of adjusted EPS and adjusted EBITDA.

Adjusted EPS and adjusted EBITDA do not have standardized meanings prescribed by GAAP. The Company's method of calculating these items may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies. Reconciliation of adjusted EBITDA to net income and GAAP EPS (diluted) to adjusted EPS (diluted) are shown below:

                                             For the three    For the twelve
                                              months ended      months ended
                                               December 31,      December 31,
                                             2009     2008     2009     2008
                                          -------- -------- -------- --------
                                                      (in thousands)

    Adjusted EBITDA                       $30,413  $14,679  $94,712  $42,474

    Amortization of Intangible Assets      (2,246)  (3,088)  (9,724)  (9,365)

    Depreciation of Property & Equipment   (2,033)  (1,900)  (8,014)  (6,615)

    Stock-Based Compensation               (1,180)  (1,074)  (3,657)  (4,080)

    Other Income (Expense)                   (651)    (734)    (589)    (719)

    Interest Income (Expense), Net         (1,967)  (1,193)  (4,643)  (1,391)

    Income Tax (Expense)                   (7,143)  (1,740) (22,024)  (5,191)
                                          -------- -------- -------- --------

    Net Income                            $15,193  $ 4,950  $46,061  $15,113
                                          -------- -------- -------- --------
                                          -------- -------- -------- --------



                                             For the three    For the twelve
                                              months ended      months ended
    Non-GAAP Adjusted Earnings Per Share       December 31,      December 31,
    (in thousands, except per share data)    2009     2008     2009     2008
                                          -------- -------- -------- --------

    Net Income                            $15,193  $ 4,950  $46,061  $15,113

    Amortization of NMHC Intangibles        1,679    2,680    7,583    7,769

    Tax effect of NMHC Intangibles           (537)    (697)  (2,453)  (1,986)
                                          -------- -------- -------- --------

    Adjusted net income                   $16,335  $ 6,933  $51,191  $20,896
                                          -------- -------- -------- --------
                                          -------- -------- -------- --------

    Adjusted EPS                          $  0.52  $  0.28  $  1.91  $  0.89

    (2) On April 30, 2008, SXC closed the acquisition of NMHC. As a result,
        SXC has introduced new segmentation and presentation of its financial
        results. Revenue is now segmented into two groups: Pharmacy Benefits
        Management ("PBM") which includes informedRx as well as mail-order
        and specialty pharmacies, and Healthcare Information Technology
        ("HCIT"). SXC records PBM revenue from NMHC exclusively on a gross
        basis which equates to the prescription price paid by consumers plus
        an administrative fee. The HCIT business records revenue only on the
        basis of the administrative fee; drug ingredient cost is not included
        in revenues or cost of claims.

The net effect is that SXC's year-over-year revenues have increased dramatically while gross profit margin and adjusted EBITDA have increased in absolute dollar terms, but have declined as a percentage of total sales. These changes do not affect profitability on an absolute dollar or per share basis.

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefit management ("PBM") services and Healthcare Information Technology ("HCIT") solutions to the healthcare benefits management industry. As the industry's "Technology-Enabled PBM"(TM), SXC's product offerings and solutions combine a wide range of advanced PBM services, software applications, application service provider processing services, and professional services to help healthcare organizations reduce the cost of prescription drugs and deliver better healthcare to their members. SXC serves many of the largest organizations in the pharmaceutical supply chain, such as health plans; employers; federal, provincial, and state governments; institutional pharmacies; pharmacy benefit managers; and retail pharmacy chains. SXC is headquartered in Lisle, Illinois with multiple locations across North America. Learn more at www.sxc.com.

Forward-Looking Statements

Certain statements included herein, including those that express management's expectations or estimates of our future performance, constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause our actual financial results, performance, or achievements to be materially different from our estimated future results, performance or achievements expressed or implied by those forward-looking statements. Numerous factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, our ability to achieve increased market acceptance for our product offerings and penetrate new markets; consolidation in the healthcare industry; the existence of undetected errors or similar problems in our software products; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; our ability to compete successfully; potential liability for the use of incorrect or incomplete data; the length of the sales cycle for our healthcare software solutions; interruption of our operations due to outside sources; our dependence on key customers; maintaining our intellectual property rights and litigation involving intellectual property rights; our ability to obtain, use or successfully integrate third-party licensed technology; compliance with existing laws, regulations and industry initiatives and future change in laws or regulations in the healthcare industry; breach of our security by third parties; our dependence on the expertise of our key personnel; our access to sufficient capital to fund our future requirements; and potential write-offs of goodwill or other intangible assets. This list is not exhaustive of the factors that may affect any of our forward-looking statements. Other factors that should be considered are discussed from time to time in SXC's filings with the U.S. Securities and Exchange Commission, including the risks and uncertainties discussed under that captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2008 Annual Report on Form 10-K and subsequent Form 10-Qs, which are available at www.sec.gov. Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to SXC or persons acting on our behalf are expressly qualified in their entirety by this notice. We disclaim any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Certain of the assumptions made in preparing forward-looking information and management's expectations include: maintenance of our existing customers and contracts, our ability to market our products successfully to anticipated customers, the impact of increasing competition, the growth of prescription drug utilization rates at predicted levels, the retention of our key personnel, our customers continuing to process transactions at historical levels, that our systems will not be interrupted for any significant period of time, that our products will perform free of major errors, our ability to obtain financing on acceptable terms and that there will be no significant changes in the regulation of our business.

                         SXC HEALTH SOLUTIONS CORP.
                         Consolidated Balance Sheets


                                                          December 31,
                                                  ---------------------------
                                                       2009          2008
                                                  ------------- -------------
                                            (in thousands, except share data)
    ASSETS

    Current assets
      Cash and cash equivalents                     $  304,370    $   67,715
      Restricted cash                                   14,169        12,498
      Short term investments                             4,639             -
      Accounts receivable, net of allowance
       for doubtful accounts of $2,871
       (2008 - $3,570)                                  97,330        80,531
      Rebates receivable                                17,630        29,586
      Prepaid expenses and other assets                  4,483         4,455
      Inventory                                          7,106         6,689
      Income tax recoverable                               345         1,459
      Deferred income taxes                              9,875        10,219
                                                  ------------- -------------
        Total current assets                           459,947       213,152
      Property and equipment, net of
       accumulated depreciation of $27,421
       (2008 - $19,449)                                 19,880        20,756

    Goodwill                                           141,787       143,751
    Other intangible assets, net of accumulated
     amortization of $23,831 (2008 - $14,099)           37,574        46,406
    Deferred financing charges                               -         1,481
    Deferred income taxes                                1,641         1,323
    Other assets                                         1,251         1,474
                                                  ------------- -------------
    Total assets                                    $  662,080    $  428,343
                                                  ------------- -------------
                                                  ------------- -------------

    LIABILITIES AND SHAREHOLDERS' EQUITY

    Current liabilities
      Accounts payable                              $    9,916    $    8,302
      Customer deposits                                 14,832        11,875
      Salaries and wages payable                        12,349        15,681
      Accrued liabilities                               30,786        32,039
      Pharmacy benefit management rebates payable       46,606        36,326
      Pharmacy benefit claim payments payable           61,669        51,406
      Deferred revenue                                   7,304         7,978
      Current portion of long-term debt                      -         3,720
                                                  ------------- -------------
        Total current liabilities                      183,462       167,327

    Long-term debt, less current installments                -        43,920
    Deferred income taxes                               13,597        15,060
    Deferred lease inducements                           2,748         3,217
    Deferred rent                                        1,337         1,461
    Other liabilities                                    2,442         3,195
                                                  ------------- -------------
      Total liabilities                                203,586       234,180
                                                  ------------- -------------

    Commitments and contingencies

    Shareholders' equity
      Common shares: no par value, unlimited
       shares authorized; 30,057,281 shares
       issued and outstanding at December 31,
       2009 (2008 - 24,103,032 shares)                 361,530       146,988
      Additional paid-in capital                        15,153        11,854
      Retained earnings                                 81,812        35,751
      Accumulated other comprehensive loss                  (1)         (430)
                                                  ------------- -------------
        Total shareholders' equity                     458,494       194,163

                                                  ------------- -------------
    Total liabilities and shareholders' equity      $  662,080    $  428,343
                                                  ------------- -------------
                                                  ------------- -------------


                         SXC HEALTH SOLUTIONS CORP.
                    Consolidated Statements of Operations
                    (in thousands, except per share data)

                            Three months ended
                               December 31,        Years ended   December 31,
                           2009          2008          2009          2008
                      ------------- ------------- ------------- -------------
    Revenue:
      PBM              $   416,803   $   269,802   $ 1,335,961   $   771,840
      HCIT:

        Transaction
         processing         15,373        14,606        61,225        52,773
        Maintenance          4,743         4,059        18,427        16,397
        Professional
         services            4,706         2,787        15,336        13,480
        System sales         1,691         1,512         7,685         8,449
                      ------------- ------------- ------------- -------------
    Total revenue          443,316       292,766     1,438,634       862,939

    Cost of revenue:
      PBM                  378,149       241,633     1,197,757       702,333
      HCIT                  12,643        13,853        54,277        45,120
                      ------------- ------------- ------------- -------------
    Total cost
     of revenue            390,792       255,486     1,252,034       747,453
                      ------------- ------------- ------------- -------------
    Gross profit            52,524        37,280       186,600       115,486

    Expenses:

      Product
       development
       costs                 2,927         2,680        11,951        10,105
      Selling, general
       and adminis-
       trative              20,940        21,501        85,797        68,792

      Depreciation of
       property and
       equipment             1,457         1,394         5,811         4,810
      Amortization
       of intangible
       assets                2,246         3,088         9,724         9,365
                      ------------- ------------- ------------- -------------
                            27,570        28,663       113,283        93,072
                      ------------- ------------- ------------- -------------

    Operating income        24,954         8,617        73,317        22,414

    Interest income           (184)         (540)         (756)       (2,749)
    Interest expense         2,151         1,733         5,399         4,140
                      ------------- ------------- ------------- -------------
      Net interest
       expense               1,967         1,193         4,643         1,391

    Other expense, net         651           734           589           719
                      ------------- ------------- ------------- -------------

    Income before
     income taxes           22,336         6,690        68,085        20,304

    Income tax
     expense (benefit):
      Current                6,467          (469)       22,285         4,866
      Deferred                 676         2,209          (261)          325
                      ------------- ------------- ------------- -------------
                             7,143         1,740        22,024         5,191

                      ------------- ------------- ------------- -------------
    Net income         $    15,193   $     4,950   $    46,061   $    15,113
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------

    Earnings
     per share:
      Basic            $      0.51   $      0.21   $      1.77   $      0.66
      Diluted          $      0.49   $      0.20   $      1.72   $      0.65

    Weighted average
     number of
     shares used
     in computing
     earnings
     per share:
       Basic            30,018,830    24,055,909    26,004,204    22,978,466
       Diluted          31,165,324    24,603,214    26,797,373    23,413,011



                         SXC HEALTH SOLUTIONS CORP.
                    Consolidated Statements of Cash Flows
                               (in thousands)

                            Three months ended             Years ended
                               December 31,               December 31,
                           2009          2008          2009          2008
                      ------------- ------------- ------------- -------------

    Cash flows from
     operating
     activities:

      Net income       $    15,193   $     4,950   $    46,061   $    15,113
      Items not
       involving cash:
        Stock-based
         compensation        1,180         1,074         3,657         4,080
        Depreciation of
         property and
         equipment           2,033         1,900         8,014         6,615
        Amortization of
         intangible
         assets              2,246         3,088         9,724         9,365
        Deferred lease
         inducements and
         rent                 (109)          (98)         (593)         (304)
        Deferred income
         taxes                 676         2,209          (261)          325
        Tax benefit on
         option exercises   (1,017)            1        (4,464)         (798)
      Changes in
       operating
       assets and
       liabilities, net
       of effects from
       acquisitions:
        Accounts
         receivable         (7,261)          147       (16,705)        8,005
        Rebates
         receivable          2,947        (5,400)       11,956        (2,383)
        Restricted cash     (1,736)        5,292        (1,671)          632
        Unbilled revenue         -         1,019            73         1,122
        Prepaid expenses       230          (808)          (72)          107
        Inventory              (83)           88          (401)          (83)
        Income tax
         recoverable           893          (941)        6,098           677
        Accounts payable     4,017         1,182         1,635         1,678
        Accrued liabilities  2,436         9,297        (1,139)        4,845
        Pharmacy benefit
         claim payments
         payable             9,861        (1,254)       10,263          (205)
        Pharmacy benefit
         management rebates
         payable             2,776        (3,277)       10,280        (8,357)
        Deferred revenue    (1,039)        1,698          (630)        1,305
        Customer deposits    2,279           580         2,957          (490)
        Other                1,269           238         1,602           335
                      ------------- ------------- ------------- -------------
      Net cash
       provided by
       operating
       activities           36,791        20,985        86,384        41,584

    Cash flows from
     investing
     activities:

      Acquisitions,
       net of cash
       acquired                  -        (2,207)       (2,176)     (104,769)
      Purchases of
       property and
       equipment            (2,383)       (2,440)       (8,994)       (8,410)
      Lease
       inducements
       received                  -             -             -           373
      Purchases of
       short term
       investments          (5,098)            -        (5,098)            -
      Proceeds from
       the sale of
       short term
       investments             449             -           449             -
                      ------------- ------------- ------------- -------------
        Net cash used
         in investing
         activities         (7,032)       (4,647)      (15,819)     (112,806)

    Cash flows from
     financing
     activities:

      Issuance of
       long-term debt            -             -             -        48,000
      Proceeds from
       public offering,
       net of issuance
       costs                  (986)            -       203,121             -
      Payment of
       financing
       costs                     -             -             -        (1,792)
      Repayment of
       long-term debt      (45,120)         (120)      (47,640)         (360)
      Proceeds from
       exercise of
       options                 347           109         6,264         1,549
      Tax benefit on
       option exercises      1,017            (1)        4,464           798
                      ------------- ------------- ------------- -------------
        Net cash
         provided by
         (used in)
         financing
         activities        (44,742)          (12)      166,209        48,195
    Effect of foreign
     exchange on cash
     balances                 (169)         (201)         (119)         (187)
                      ------------- ------------- ------------- -------------

    Increase (decrease)
     in cash and cash
     equivalents           (15,152)       16,125       236,655       (23,214)

    Cash and cash
     equivalents,
     beginning of
     period                319,522        51,590        67,715        90,929
                      ------------- ------------- ------------- -------------

    Cash and cash
     equivalents, end
     of period         $   304,370   $    67,715   $   304,370   $    67,715
                      ------------- ------------- ------------- -------------
                      ------------- ------------- ------------- -------------

SOURCE SXC Health Solutions Corp.

Back to top
'/>"/>
SOURCE SXC Health Solutions Corp.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology: